6 completed, 2 recruiting, 1 not yet recruiting. 2 Not applicable, 2 Phase 3, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow MDR-TB: new trials by email Literature Review of MDR-TB trials Research Report on MDR-TB
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR) Bedaquiline Oral Tablet - MDR-TB, Tuberculosis Multi Drug Resistant Active | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 55 | 2026-09-11 | 2026-09-16 |
| Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) Acetohydroxamic Acid, Placebo - Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 120 | 2026-02-21 | 2026-02-06 |
| HIV and Multi-Drug Resistant Tuberculosis: a Study on Clinical Outcomes Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB) - HIV Infection, MDR-TB | Completed | Zahedan University of Medical Sciences | 222128 | 2024-05-15 | 2024-11-04 | |
| A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB Vγ2Vδ2 T lymphocyte-based immunotherapy, Treatment regimens for MDR-TB - MDR-TB, Immunotherapy | Phase 4 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 30 | 2022-08-03 | 2022-08-10 |
| Triage Test for All Oral DR-TB Regimen (TRiAD Study) Xpert® MTB/XDR - Drug Resistant Tuberculosis, MDR-TB | Completed | Centre for the AIDS Programme of Research in South Africa | 786 | 2022-05-26 | 2025-06-26 | |
| A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB PRS Regimen V, MDR-TB Treatment Regimen(WHO) - MDR-TB | Phase 4 | Completed | Shanghai Pulmonary Hospital, Shanghai, China | 60 | 2021-04-01 | 2024-12-03 |
| Saliva and Dried Blood Spot Therapeutic Drug Monitoring for MDR-TB in Tanzania Therapeutic drug monitoring (TDM) - MDR-TB | Not applicable | Completed | Jan-Willem C Alffenaar | 51 | 2019-09-24 | 2020-10-30 |
| The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline), Moxifloxacin, Clofazimine - MDR-TB | Phase 3 | Completed | IUATLD, Inc | 588 | 2016-03-01 | 2023-09-28 |
| A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes NCM-Plus - MDR-TB, HIV | Not applicable | Completed | Johns Hopkins University | 2844 | 2014-10-01 | 2026-10-06 |
Tuberculosis, Multidrug-Resistant (9) · Extensively Drug-Resistant Tuberculosis (1) · HIV Infections (1) · Tuberculosis (1)
Actinomycetales Infections (9) · Bacterial Infections (9) · Bacterial Infections and Mycoses (9) · Gram-Positive Bacterial Infections (9) · Infections (9) · Mycobacterium Infections (9) · Tuberculosis (8) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Lentivirus Infections (1) · RNA Virus Infections (1) · Retroviridae Infections (1)
bedaquiline (2) · Clinical Protocols (1) · Clofazimine (1) · Drug Combinations (1) · Drug Monitoring (1) · Ethambutol (1) · Isoniazid (1) · Kanamycin (1) · Levofloxacin (1) · Moxifloxacin (1) · Prothionamide (1) · Pyrazinamide (1) · acetohydroxamic acid (1)
Shanghai Pulmonary Hospital, Shanghai, China (3) · Assistance Publique - Hôpitaux de Paris (1) · Centre for the AIDS Programme of Research in South Africa (1) · IUATLD, Inc (1) · Jan-Willem C Alffenaar (1) · Johns Hopkins University (1) · Zahedan University of Medical Sciences (1)
China (3) · South Africa (3) · Ethiopia (2) · France (1) · Georgia (1) · India (1) · Iran (1) · Moldova (1) · Mongolia (1) · Nigeria (1) · Tanzania (1) · Uganda (1)
Andrew Nunn, PhD (1) · Jason E Farley, PhD, MPH, NP (1) · Kogieleum Naidoo, MBCHB, PHD (1) · Sarah Meredith, MD (1) · Stellah Mpagama, PhD (1)
PMID 26929418, PMID 30865791, PMID 33675664, PMID 38178293, PMID 38389038, PMID 38462751, PMID 39609025